Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma

Cancer

Volumn 88, Issue 10, 2000, Pages 2252-2259

  Janni, Wolfgang ^a   Gastroph, Stephan ^a   Hepp, Florian ^a   Kentenich, Christina ^a   Rjosk, Dorothea ^a   Schindlbeck, Christian ^a   Dimpfl, Thomas ^a   Sommer, Harald ^a   Braun, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Breast neoplasm; Disseminated tumor cells; Metastasis; Micrometastases; Overall survival; Prognosis; Recurrence

Indexed keywords

ARTICLE; BONE MARROW METASTASIS; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TUMOR CELL;

BONE MARROW; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034657595     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000515)88:10<2252::AID-CNCR8>3.0.CO;2-Q     Document Type: Article

References (38)

1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
2. Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995; 87:1441-5.
3. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991;83:154-5.
4. Clark GM, Sledge-GW J, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61.
5. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-40.
6. Kamby C, Rose C, Ejlertsen B, Andersen J, Birkler NE, Rytter L, et al. Stage and pattern of metastases in patients with breast cancer. Eur J Cancer Clin Oncol 1987;23:1925-34.
7. Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 1998;152: 396-411.
8. Rummans TA, Frost M, Suman VJ, Taylor M, Novotny P, Gendron T, et al. Quality of life and pain in patients with recurrent breast and gynecologic cancer. Psychosomatics 1998;39:437-45.
9. Gorins A. Quality of life. Eur J Gynaecol Oncol 1996;17:5-6.
10. Braun S, Pantel K, Janni W, Hepp F, Kentenich CRM, Müller P, et al. Cytokeratin-positive occult metastatic cells in bone marrow and survival of breast cancer patients with stage I-III disease. N Engl J Med 2000;342:525-33.
11. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996;88:1652-8.
12. Kamby C, Guldhammer B, Vejborg I, Rossing N, Dirksen H, Daugaard S, et al. The presence of tumor cells in bone marrow at the time of first recurrence of breast cancer. Cancer 1987;60:1306-12.
13. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999;354: 197-202.
14. Braun S, Muller M, Hepp F, Schlimok G, Riethmuller G, Pantel K. Re: micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1998;90:1099-101.
15. Brugger W, Buhring HJ, Grunebach F, Vogel W, Kaul S, Muller R, et al. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol 1999;17:1535-44.
16. Braun S, Pantel K. Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat 1998;52:201-16.
17. Pantel K, Felber E, Schlimok G. Detection and characterization of residual disease in breast cancer. J Hematother 1994; 3:315-22.
18. Stigbrand T, Andres C, Bellanger L, Bishr OM, Bodenmuller H, Bonfrer H, et al. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop. Tumour Biol 1998;19:132-52.
19. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
20. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980;45:2220-4.
21. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
22. Breimann L, Friedmann JH, Olsken RA. Classification and regression trees. Belmont, CA: Waelswoth, 1984.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
24. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
25. Halverson KJ, Perez CA, Kuske RR, Garcia DM, Simpson JR, Fineberg B. Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 1992;23:285-91.
26. Mansi JL, Berger U, McDonnell T, Pople A, Rayter Z, Gazet JC, et al. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 1989;7:445-9.
27. Molino A, Pelosi G, Turazza M, Sperotto L, Bonetti A, Nortilli R, et al. Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features and prognosis. Breast Cancer Res Treat 1997;42:23-30.
28. Mueller P, Carroll P, Bowers E, Moore D, Cher M, Presti J, et al. Low frequency epithelial cells in hone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer 1998;83:538-46.
29. Klein CA, Schmidt KO, Schardt JA, Pantei K, Speicher MR, Riethmuller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA 1999;96:4494-9.
30. Travers MT, Barrett-Lee PJ, Berger U, Luqmani YA, Gazet JC, Powles TJ, et al. Growth factor expression in normal, benign, and malignant breast tissue. Br Med J (Clin Res Ed) 1988; 296:1621-4.
31. Haubold-Reuter BG, Duewell S, Schilcher BR, Marincek B, von Schulthess GK. The value of hone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study. Eur J Nucl Med 1993;20:1063-9.
32. Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 1999;23:123-9.
33. Theissen P, Smolarz K, Scharl A, Groth A, Scheidhauer K, Voth F., et al. Magnetic resonance imaging in screening for hone metastasis? A prospective comparison with bone scintigraphy. Nuklearmedizin 1994;33:132-7.
34. Dhodapkar MV, Ingle JN, Cha SS, Mailliard JA, Wieand HS. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials. Cancer 1996;77:683-90.
35. Fey MF, Brunner KW, Sonntag RW. Prognostic factors in metastatic breast cancer. Cancer Clin Trials 1981;4:237-47.
36. Kamby C, Rose C, Iversen H, Holm NV, Andersen KW, Thorpe SM. Pattern of metastases in human breast carcinoma in relation to estrogen receptor status. Anticancer Res 1986;6:107-11.
37. Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 1999;5:3999-4004.
38. Braun S, Kentenich CRM, Janni W, Hepp F, de Waal J, Willgeroth F, et al. Prognostic value of cytokeratin (CK)-positive bone marrow micrometastases (BMM) detected in high-risk breast cancer patients after adjuvant chemotherapy. J Clin Oncol 2000;18:80-6.